Home › Pancreatic Cancer › NCT02478892

Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk

Who can join

Ages 18 and older · All sexes

Inclusion Criteria

* Age \>= 18
* Documented germline pathogenic or likely pathogenic BRCA1, BRCA2, ATM, or PALB2 mutation
* If no history of PDAC in a first or second degree relative, age \>= 50
* If there is a history of PDAC in a first or second degree relative, minimum age of eligibility is 10 years younger than the age of onset of the youngest relative with pancreatic cancer

Exclusion Criteria

• Pregnancy

About the study

The study is a prospective, observational study evaluating the utility of endoscopic ultrasound or MRI for the identification of preneoplastic and neoplastic pancreatic lesions in patients at high risk for pancreatic cancer, specifically those with BRCA1/2, ATM, or PALB2 mutations.

What is being tested

• Collection of data from endoscopic ultrasound or MRI/MRCP of the abdomen (other)
• Blood sample collection for research (other)

Sponsor: Abramson Cancer Center at Penn Medicine · Participants: 200 · Started: 2015-05

Contact the study team

Official record on ClinicalTrials.gov — NCT02478892

Locations in the U.S.

Conditions

• Pancreatic Cancer

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.